Breathe Well Live Well
|
GSK's Nucala gets FDA nod in asthma maintenance
BioWorld Online The FDA added another drug to the asthma armamentarium, with the approval of Glaxosmithkline plc's Nucala (mepolizumab) as a maintenance therapy for patients who have a history of severe asthma attacks despite being on treatment. Approval, disclosed … |
View full post on asthma – Google News
|
FDA approves Nucala to treat severe asthma
FDA.gov The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe … FDA Approves New Asthma Medication |
View full post on asthma – Google News
|
Glaxo's Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Yahoo News Several companies including Teva Pharmaceutical Industries Limited TEVA and AstraZeneca plc AZN are looking to bring their anti IL-5 antibodies to the market for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD). |
View full post on asthma – Google News
BioPharma Dive |
Glaxos Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Zacks.com In the U.S., the drug is approved for both COPD and asthma. We note that Glaxo has a collaboration agreement with Theravance for Relvar/Breo Ellipta and Anoro Ellipta (COPD). Relvar/Breo Ellipta generated sales of £94 million in the first half of 2015. After bad news on Breo, Glaxo's monthly asthma drug wins an EU rec |
View full post on asthma – Google News
Lung Disease News |
FDA Committee Recommends Approval Of Nucala For Adult Asthma Patients
Lung Disease News An FDA advisory committee recently voted unanimously to approve Nucala for the treatment of severe asthma with eosinophilic inflammation in patients 18 and older. The committee, however, decided against the use of the therapy in adolescents aged … GSK's new asthma biologic gains FDA panel backing |
View full post on asthma – Google News